HKPD vs MCK
Cellyan Biotechnology Co. Ltd. and McKesson Corp., side by side — 3 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | HKPD | MCK |
|---|---|---|
| Revenue | $20.3M | $403.4B |
| Net income | $-27,056 | $4.8B |
| Gross margin | 11.9% | 3.6% |
| Net margin | −0.1% | 1.3% |
| Return on equity | −0.6% | · |
| Diluted EPS | −$0.00 | $38.38 |
| Dividend / share | · | $3.17 |
| Payout ratio | · | 8.0% |
| Free cash flow | $499,298 | $5.7B |
| Equity | $5.0M | $-2.2B |
| Net debt / equity | 0.23× | · |
| Current ratio | 2.99× | 0.85× |
| Revenue CAGR 5y | · | 11.1% |
| Profit CAGR 5y | · | · |
MCK bills 19859.9× the revenue of HKPD, and HKPD closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
3 years side by side
| Fiscal year | HKPD | MCK |
|---|---|---|
| FY2024 | $20.3M | $359.1B |
| FY2023 | $16.7M | $309.0B |
| FY2022 | $12.6M | $276.7B |
Bottom line
| Fiscal year | HKPD | MCK |
|---|---|---|
| FY2024 | $-27,056 | $3.3B |
| FY2023 | $1.3M | $3.0B |
| FY2022 | $998,196 | $3.6B |
Standard deviation, each side
HKPD's net margin has been more volatile than MCK's over the 3 comparable fiscal years — 3.8 percentage points of standard deviation against 0.2.
3 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between HKPD and MCK over these 3 fiscal years — HKPD led in 2 and MCK in 1.
3 of 18 comparable fiscal years — a year missing data on either side is not counted.